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Dr Lamarchedoi:10.1016/j.jtcvs.2004.09.011Objective: Cardiopulmonary bypass triggers a systemic inflammatory response that
alters pulmonary endothelial function, which can contribute to pulmonary hyper-
tension. Milrinone is a type III phosphodiesterase inhibitor. The objective of this
study was to compare the effects of inhaled and intravenous milrinone on the
pulmonary endothelium–dependent relaxations and hemodynamic and oxygenation
parameters after cardiopulmonary bypass in a porcine model.
Methods: Five groups of Landrace swine were compared: (1) control group, no
cardiopulmonary bypass; (2) bypass group, 90 minutes of normothermic bypass and
60 minutes of reperfusion; (3) inhaled milrinone group, bypass preceded by a
1.8-mg bolus of inhaled milrinone followed by a continuous milrinone nebulization;
(4) intravenous milrinone group, bypass preceded by 2 mg of intravenous milrinone;
and (5) inhaled NaCl group, bypass preceded by inhaled saline solution. After
sacrifice, pulmonary arterial endothelium–dependent relaxations to acetylcholine
and bradykinin were studied in organ chambers.
Results: Inhaled milrinone caused less hypotension (P  .05), a lesser decrease in
peripheral vascular resistances (P  .01), and a lower heart rate (P  .05) than
intravenous milrinone. Inhaled milrinone prevented the alterations in relaxations of
pulmonary arteries to acetylcholine caused by cardiopulmonary bypass, and relax-
ations to bradykinin were improved in the inhaled milrinone group (P  .05)
compared with the cardiopulmonary bypass and control groups.
Conclusions: Inhaled milrinone prevents the occurrence of the pulmonary endothelial
dysfunction seen after cardiopulmonary bypass. The hemodynamic and oxygenation
profiles obtained with inhaled milrinone are safer than with intravenous milrinone.
These strategies might be useful in preventing pulmonary hypertension after cardiac
surgery.
Cardiopulmonary bypass (CPB) induces a systemic inflammatory response thataffects all organ systems. The physiologic alterations after CPB were recognizedearly after the development of CPB in the 1950s. The postpump syndrome is
characterized by an increase in pulmonary capillary permeability, leading to decreased
oxygenation, increased alveolar-arterial oxygen gradient, decreased pulmonary compli-
ance, and an increased pulmonary vascular resistance.1,2 Among the most important
repercussions of the inflammatory cascade are those on the pulmonary vasculature.
During CPB, blood flow is diverted from the right atrium to the CPB pump, goes
through an oxygenator membrane, and is pumped back into the aorta, and thus the lungs
are minimally perfused during CPB. At separation from CPB, the lungs are reperfused
and experience ischemia-reperfusion injury caused by exposure to large amounts of free
radicals. Because of the contact of the blood elements with the nonphysiologic surface
of the bypass circuit, neutrophils and platelets are activated and contribute to pulmonary
damage, which triggers endothelial dysfunction after CPB.3,4 After CPB, the damage to
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CSPthe pulmonary endothelium can lead to pulmonary hyperten-
sion (PH), leading to an increase in right ventricular work.
Right ventricular dysfunction after CPB carries a poor prog-
nosis, with a perioperative mortality ranging from 44% to
86%.5
The endothelium has an important role in regulating the
vascular tone by releasing several vasorelaxing substances,
such as nitric oxide (NO) and prostacyclin (PGI2), and
vasoconstrictors, such as endothelin and thromboxanes. The
ability to induce vasorelaxation can be decreased when
endothelial dysfunction is present.6 Several pharmacologic
TABLE 1. Hemodynamic data throughout the experiment
Before Rx A
SEM
MAP CPB 59.8 2.2 —
Inhaled
milrinone
72.8 5.2 60.1
Inhaled NaCl 79 12.6 71
IV milrinone 79.6 5.1 55
CI CPB 4.8 1 —
Inhaled
milrinone
3.6 0.3 3.2
Inhaled NaCl 4.0 0.1 3.9
IV milrinone 2.9 0.2 3.5
HR CPB 95.2 6.3 —
Inhaled
milrinone
76.3 3.2 75
Inhaled NaCl 86 13 71
IV milrinone 80.1 8.7 96
W CPB 7.3 1.1 —
Inhaled
milrinone
5.2 1 10.5
Inhaled NaCl 6.6 0.7 6
IV milrinone 5 0 3.3
mPAP CPB 12 1.2 —
Inhaled
milrinone
10.5 1 4
Inhaled NaCl 11.6 2.3 11.3
IV milrinone 18.3 7.4 20
CVP CPB 4 0.9 —
Inhaled
milrinone
4.2 1.1 2.8
Inhaled NaCl 5 1.5 6
IV milrinone 1.7 0.3 1
A-aDO2 CPB 100 14 —
Inhaled
milrinone
134 20 —
Inhaled NaCl 156 40.8 —
IV milrinone 162 17 —
Rx, Experimental drug; CPB, mean cardiopulmonary bypass; MAP, mean
pressure; mPAP, pulmonary artery pressure; CVP, central venous pressur
**P  .01 versus inhaled milrinone. ***P  .001 versus inhaled milrinone
rinone. &&P  .01 versus CPB. $P  .05 versus NaCl. $$P  .011 versusagents have been used to limit the increase in pulmonary
84 The Journal of Thoracic and Cardiovascular Surgery ● July 2vascular resistance and PH after cardiac surgery, including
intravenous nitroglycerin, intravenous milrinone, inhaled
NO, and inhaled PGI2.
Milrinone, a phosphodiesterase III inhibitor that increases
intracellular levels of cyclic adenosine monophosphate
(cAMP), induces positive cardiac inotropy and systemic va-
sorelaxation. When administered intravenously, milrinone de-
creases systemic vascular resistances, causing hypotension,
which can be hazardous in the hours after cardiac surgery. The
use of inhaled milrinone has recently been described by
Haraldsson and colleagues7 to avoid the systemic hypotension
x 15 min on CPB 45 min on CPB
SEM SEM SEM
— 68 7 66 5.8
4.1 74.1 5.7 68.6 3.8
10.4 78.6 10.2 74.6 9.4
3.6 71 11 74.6 10.8
— 4.6 0.3 4.5 0.3
0.4 3.9 0.3 4.0 0.3
0.2 4.3 0.5 4.4 0.4
0.8 4.5 0.2 4.5 0.2
— 89 10.5** 95.4 9.5***
4.7 62.2 3.5$$$ 66 3.9$$$
3 92 2 92 7
19.5 106.3 4.9 117.7 6.2
— — — — —
0.7 — — — —
1 — — — —
0.3 — — — —
— — — — —
0.3 — — — —
1.2 — — — —
3.2 — — — —
— — — — —
1.2 — — — —
3 — — — —
0 — — — —
— 218 36 188 13
— 178 12 181 16
— 216 27.5 183 23
— 174 1 168 4
al pressure; IV, intravenous; CI, cardiac index; HR, heart rate; W, wedge
DO2, alveolar-arterial oxygen gradient. *P  .05 versus inhaled milrinone.
 .05 versus intravenous milrinone. $$$P  .001 versus intravenous mil-
l. $$$P  .001 versus NaCl.fter R
arteri
e; A-a
. $Passociated with intravenous milrinone. They observed a de-
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Pcrease in pulmonary artery pressure (PAP) without systemic
hypotension. In a recent randomized controlled trial comparing
the use of intravenous milrinone with that of placebo in pa-
tients with congestive heart failure, intravenous milrinone low-
ered the systemic arterial pressure and accelerated the heart
rate, but there was no clinical benefit compared with placebo.8
Our main hypothesis is that inhaled milrinone could prevent
post-CPB pulmonary endothelial dysfunction and reduce the
pulmonary arterial pressure without the systemic side effects
known for intravenous milrinone in patients undergoing car-
75 min on CPB 30 min
SEM
70.4 5.3 85.6
68 3.2 65.33
84.6 6.2 73.5
75 8.6 61
4.85 0.3 7.2
4.04 0.2 3.9
4.6 0.3 6.21
4.6 0.2 3.89
112.4 4.9***$ 92.2
64.7 3.8$$$ 73.7
98 12 115
141.3 14.3 108.7
— — 5.5
— — 2.5
— — 7.5
— — 4
— — 17.6
— — 13
— — 13.7
— — 15.7
— — 4.7
— — 2.3
— — 3.5
— — 5.7
196 17 181
186 20 165
193.7 22.7 216.2
160 7 277diac surgery. The aim of the present study was to compare the
The Journal of Thoraceffects of inhaled and intravenous milrinone in a swine model
of CPB on pulmonary endothelial function, hemodynamics,
and oxygenation. The levels of cAMP were also compared to
document the mechanism of action of the drug.
Material and Methods
Experimental Preparation for All Groups (Anesthesia)
All experiments were performed with Landrace swine (McGill
University, Montreal, Quebec, Canada) of either sex aged 8 weeks
and weighing 25  3 kg. Animals were maintained and tested in
r CPB 60 min after CPB
SEM SEM
5.1 61.4 4.4*$
6.1 54.8 3.5
5.3 62 5.5
14.8 44.6 13.7
0.7 4.8 0.2**$$
0.4 4.4 0.3
1.7 3.9 0.3
0.6 3.3 1.3
5.9* 92.6 2.5*
3.4$$$ 73.7 4.6$
24 106 13
10.3 95.3 4.6
2.1 3.9 1.4
0.7 2.4 0.6
2 3.5 1.22
1.6 11.7 0.4
0.8 14 1.4
0.9 13.1 1.07
2 13.7 2
1.2 17.3 1.9
1.5 3 0.5
0.7 2 0.8
2.9 2.6 1.2
4.3 5.7 3.7
31 156 23
17 193 27
6.8 199.8 12.2
92 360 56&&**$$afteaccordance with the recommendations of the guidelines on the
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CSPCare and Use of Laboratory Animals issued by the Canadian
Council on Animals and approved by a local ethics committee. The
piglets were fasted for 12 hours before the operation and were
sedated with intramuscular ketamine hydrochloride (25 mg/kg;
Ayerst Veterinary Laboratories, Guelph, Ontario, Canada) and
xylazine (10 mg/kg; Boehringer Ingelheim, Burlington, Ontario,
Canada). Induction was achieved by using mask ventilation with
2% isoflurane (Abbott Laboratories Limited, St-Laurent, Quebec,
Canada).
The animals were subsequently intubated and mechanically
ventilated with a constant oxygen and air mixture (3:2 or fraction
of inspired oxygen  0.66) at 14 breath strokes per minute and a
tidal volume of 6 to 8 mL/kg. Anesthesia was maintained with 1%
isoflurane inhalation. Skin was prepared and draped with a sterile
field. Arterial and venous blood gases were measured at regular
intervals and maintained within physiologic limits by adjusting
ventilation rate and tidal volume. An electrocardiogram was re-
corded from 4 subcutaneous limb and 1 precordial electrodes.
Experimental Groups
Group 1: Control (n  6). After skin preparation, the medi-
astinum was exposed through a median sternotomy. Heparin (300
IU/kg; Leo Pharma, Inc, Ajax, Ontario, Canada) was administered
intravenously. After 1 hour of general anesthesia with 1% isoflu-
rane, the animals were exsanguinated, and the lungs were
harvested.
Group 2: CPB (90 minutes, 60 minutes of reperfusion;
n  6). After skin preparation and draping with sterile fields, the
jugular vein and carotid artery were cannulated to obtain a central
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
Figure 1. A, Rings of porcine pulmonary with endoth
(percent contraction to phenylephrine); PE, phenyleph
versus inhaled milrinone; **P< .01, CPB versus inhale
< .05, inhaled versus intravenous milrinone; P < .
versus CPB; ¶¶P < .01, control versus CPB; ¶¶¶P < .00
milrinone; ‡P< .05, control versus intravenous milrinon
Log bradykinin (mol/L); Y-axis, tension (percent con
expressed as means SEM. *P< .05, CPB versus inha
< .05, inhaled versus intravenous milrinone; P <
inhaled versus intravenous milrinone; #P < .05, CP
intravenous milrinone; ¶P < .05, control versus CPB; /P
versus inhaled milrinone; ///P < .001, control versus
TABLE 2. Contractile responses to KCl and PE
Control
KCl (g) 5.1 0.3
PE (g) 3.0 0.2
Dose PE ( 107 mol/L) 5.5  0.9
Contractile responses to a depolarizing physiologic solution containing 6
KCl-induced contraction of pulmonary arteries isolated from control pigs (n
previous inhaled (n 3) or intravenous (n 3) administration of milrinone.
are expressed as means  SD: *P  .01 versus intravenous milrinone; *milrinone; ‡P < .01, control versus intravenous milrinone;
86 The Journal of Thoracic and Cardiovascular Surgery ● July 2venous line and arterial pressure, respectively. A cystostomy was
performed for a measurement of urine output. A median sternot-
omy was performed, and the pericardium was opened for heart
exposure.
A Swan-Ganz catheter (Edwards Lifesciences, Irving, Calif)
was inserted through the jugular vein to measure PAP. After
heparin administration (400 IU/kg), a double purse string was
made on the proximal ascending aorta, and a single purse string
was made on the right atrium. A blood sample was drawn there-
after from the right atrium, and proper anticoagulation was as-
sessed with an activated coagulation time (ACT) by using the
Hemochron 801 (Technidyne, Dorval, Quebec, Canada). The aorta
and right atrium were cannulated when the ACT was greater than
300 seconds with 22F and 29/29F double-staged cannulas (DLP,
Inc, Grand Rapids, Mich), respectively. After cannulation, CPB
was initiated when the ACT was greater than 400 seconds. Ven-
tilation was stopped throughout the CPB period. Anesthesia was
maintained with the jugular vein line, with a continuous infusion
of propofol (0.1-0.2 mg · kg1 · min1; Pharmascience, Inc,
Montreal, Quebec, Canada). The CPB circuit consisted of a hol-
low-fiber membrane oxygenator with an incorporated filtered hard-
shell venous reservoir (Monolyth; Sorin, Irvine, Calif), a heater-
cooler, and a roller pump (Sarns 7000, Ann Harbor, Mich). The
circuit was primed with 500 mL of Pentaspan (10% Pentastarch;
DuPont Pharma, Inc, Mississauga, Ontario, Canada), 250 mL of
lactated Ringer’s solution, 5000 IU of heparin, 12.5 g of mannitol,
and 15/mEq of sodium bicarbonate. After initial stabilization, the
pump flow was adjusted to maintain an index of 2.4 L · min1 ·
m2 and assessed on the basis of venous gases to maintain a mixed
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™3
m. X-axis, Log acetylcholine (mol/L); Y-axis, tension
Data are expressed as means  SEM. *P < .05, CPB
rinone; ***P< .001, CPB versus inhaled milrinone;P
haled versus intravenous milrinone; ¶P < .05, control
ntrol versus CPB; †P < .05, control versus intravenous
, Rings of porcine pulmonary with endothelium. X-axis,
ion to phenylephrine); PE, phenylephrine. Data are
ilrinone; **P< .01, CPB versus inhaled milrinone;P
nhaled versus intravenous milrinone; P < .001,
rsus intravenous milrinone; ##P < .01, CPB versus
05, control versus inhaled milrinone; //P < .01, control
led milrinone; †P < .05, control versus intravenous
PB
Inhaled
milrinone
Intravenous
milrinone
 2.2 4.8 0.28 4.0  0.3
 0.1 2.7 0.1 2.4  0.1
 9.6 8.3 0.93*,** 4.1  0.3
ol/L KCl and concentration of phenylephrine required to achieve 50% of
and pigs that underwent cardiopulmonary bypass (n  6) with or without
otassium chloride; PE, phenylephrine; CPB, cardiopulmonary bypass. Data
.05 versus control.™™™™
eliu
rine.
d mil
01, in
1, co
e. B
tract
led m
.01, i
B ve
< .
inhaC
3.9
2.5
7.0
0 mm
 6)
KCl, P†††P < .001, control versus intravenous milrinone.
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PFigure 1. For legend see opposite page.
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CSPvenous saturation of greater than 60%. Mean systemic arterial
pressure was maintained between 50 and 70 mm Hg with Ringer’s
lactate and punctual boluses of 50 to 200 g of neosynephrine
(Cayman Chemical Co, Ann Arbor, Mich). The temperature was
allowed to drift to 36°C. The heart was left beating and empty. No
aortic crossclamping or cardioplegia was used. Before CPB wean-
ing, swine were rewarmed to 38°C (normal porcine temperature).
After 90 minutes of CPB, mechanical ventilation and isoflurane-
induced anesthesia were reinstituted, and the animals were weaned
from CPB. Normal circulation was restored for 60 minutes, at
which time the animal was exsanguinated into the cardiotomy
reservoir. The heart and lungs were excised en bloc and immedi-
ately immersed in a cold modified Krebs-bicarbonate solution
(NaCl, 118.3 mmol/L; KCl, 4.7 mmol/L; MgSO4, 1.2 mmol/L;
KH2PO4, 1.2 mmol/L; glucose, 11.1 mmol/L; CaCl2, 2.5 mmol/L;
NaHCO3, 25 mmol/L; and ethylenediamine tetraacetic acid, 0.026
mmol/L).
Group 3: CPB and inhaled milrinone (n  6). The same
procedure was followed as in the CPB group (group 2), with the
addition of a bolus of 1.8 mg (60-90 g/kg) of milrinone
(Primacor; Sanofi-Synthelabo Canada, Inc, Markham, Ontario,
Canada) that was administered through the endotracheal tube
through a nebulizer during the 15 minutes preceding the initi-
ation of CPB. Milrinone was given as a dilution of 2 mg of
milrinone, 1 mg/mL, diluted in 8 mL of normal saline (200
g/mL). The drug was administered through a conventional
in-line nebulizer (Salter Labs) connected to the inspiratory limb
of the ventilator. Ventilation was stopped, and a continuous
nebulization of milrinone at a rate of 0.08 to 0.11 g · kg1 ·
min1 with a continuous positive airway pressure of 3 cm H2O
was then instituted until the end of the CPB. Before weaning
from CPB, nebulization was stopped, and ventilation was
reinstituted.
Group 4: CPB with intravenous milrinone (n 3). The same
procedure was followed as in the CPB group (group 2) with the
Figure 2. Concentration of cAMP in pulmonary arterie
tration (pmol/mg proteins). Data are expressed as mea
milrinone; ¶P < .05 versus control.addition of a 2-mg (67-100 g/kg) bolus of milrinone diluted in 10
88 The Journal of Thoracic and Cardiovascular Surgery ● July 2mL of saline solution and administered intravenously over 15
minutes after the administration of heparin and before the institu-
tion of CPB.
Group 5: CPB with inhaled vehicle (0.9% NaCl, n  3). The
same procedure was followed as in the CPB group (group 2) with
the addition of a bolus of 8 mL of normal saline (0.9% NaCl) as
the vehicle used for administration of inhaled milrinone adminis-
tered through the endotracheal tube through a nebulizer during the
15 minutes preceding the initiation of CPB. The saline was ad-
ministered through a conventional inline nebulizer (Salter Labs)
connected to the inspiratory limb of the ventilator. Ventilation was
stopped, and a continuous nebulization of saline at a rate of 1.3
mL/h with a continuous positive airway pressure of 3 cm H2O was
then instituted until the end of CPB. Before weaning from CPB,
nebulization was stopped, and ventilation was reinstituted.
Hemodynamic and Biochemical Data
The heart rate was continuously monitored from 5 subcutaneous
limb electrodes. Arterial and venous blood gases were measured at
regular intervals during the experiment (baseline; during CPB at
15, 45, and 75 minutes; and at 30 and 60 minutes after weaning
from CPB) and maintained within physiologic limits by adjusting
the ventilation rate and tidal volume. Hemodynamic parameters,
including mean arterial pressure, heart rate, mean PAP, central
venous pressure, and pulmonary artery wedge pressure, were mea-
sured with a Swan-Ganz catheter at different time intervals during
the procedure: after induction, after drug administration, and after
weaning of CPB (30 and 60 minutes).
Vascular Reactivity Studies
Less than 10 minutes after en bloc excision, the heart was
removed, and the primary pulmonary artery was dissected.
Branches of second-degree pulmonary arteries were isolated
and dissected free of connective and adventitial tissue and
er CPB. X-axis, Study groups; Y-axis, cAMP concen-
SEM. *P < .05 versus CPB; P < .05 versus inhaleds aft
ns divided into rings (4 mm wide, 16 rings per animal). All rings
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Pwere placed in organ chambers (Emka Technologies, Inc, Paris,
France) filled with 20 mL of modified Krebs-bicarbonate solu-
tion continuously heated at 37°C and oxygenated with a carbo-
gen mixture (95% O2 and 5% CO2). The rings were suspended
between 2 metal stirrups, with the upper one connected to an
isometric force transducer connected to a signal amplifier and
then allowed to stabilize for 30 minutes. Data were collected
with biologic signal data acquisition software (IOX 1.700;
Emka Technologies, Inc). Each arterial ring was stretched to the
optimal point of its active length-tension curve (3.5 g), as
determined by measuring the contraction to 60 mmol/L KCl at
different levels of stretch. The maximal contraction of rings was
then obtained with the addition of KCl (60 mmol/L KCl). After
obtaining a plateau, all baths were washed twice with modified
Krebs-bicarbonate solution, and indomethacin (INN: indometa-
cin; 105 mmol/L) to exclude production of endogenous pro-
stanoids was added in each bath. After 45 minutes of stabili-
zation, phenylephrine (range, 2  107 mol/L to 3  106
mol/L) was added to obtain a contraction averaging 50% of the
maximal contraction to KCl.
Endothelium-dependent Relaxations
The NO-mediated relaxation pathway was studied by constructing
concentration-response curves to acetylcholine (109 to 105
mol/L; an agonist of M2 receptors coupled to Gi proteins) and
bradykinin (1012 to 106 mol/L; an agonist of B2 receptors
coupled to Gq proteins).
Endothelium-independent Relaxations
At the end of the experiment, endothelium-independent relaxations
were studied with the use of 105 mol/L sodium nitroprusside
(SNP), an NO donor.
Study Drugs
All drugs were prepared daily. Acetylcholine, bradykinin, indo-
methacin, and SNP were obtained from Sigma Chemical Co
(Oakville, Ontario, Canada). Propranolol was obtained from Bi-
omol Research Laboratories, Inc (Plymouth Meeting, Pa), and
phenylephrine was obtained from Cayman Chemical Co. Milri-
none was obtained from Sanofi-Synthelabo.
Determination of Pulmonary Artery Intravascular
cAMP Content
Rings from the 4 groups were collected after death, frozen in liquid
nitrogen, and stored at 70°C to determine the vascular cAMP
content of porcine pulmonary arteries. At the time of analysis, all
segments were pulverized in a liquid nitrogen–cooled stainless-
steel mortar and then transferred in trichloracetic acid solution
(6.25% wt/vol). The acid extracts were then centrifuged at 4°C for
15 minutes at 12,000g (3000 rpm) to precipitate cell debris and
proteins. The pellets were used for total protein determination by
using the Bradford microassay technique (Bio-Rad, Mississauga,
Ontario, Canada). The supernatants were extracted 4 times with
water-saturated diethyl ether to remove trichloracetic acid. Any
residual diethyl ether was removed by heating the samples to 90°C
for 3 to 5 minutes. cAMP quantitation was done by using an
enzyme immunoassay system with acetylation based on rabbit
anti-cAMP antibodies (Amersham Pharmacia Biotech, Baie
The Journal of Thoracd’Urfé, Quebec, Canada). The amount of cAMP in each blood
vessel ring was standardized to picomoles of cAMP per milligram
of protein.
Statistical Analysis
All values are expressed as means  SEM. Contractions to
phenylephrine are expressed as a percentage of the maximal
contraction to KCl (60 mmol/L). Relaxations are expressed as
the percentage of the maximal contraction to phenylephrine for
each ring. Two-way repeated analysis of variance was per-
formed to compare each point of the concentration-response
curves between control rings and CPB rings. The Student t test
for paired-unpaired observations was used for the comparison
of the PAPs and the intravascular cAMP content. Statistical
analysis was performed with the computer software SAS (SAS
Instruments, Inc, Cary, NC).
Results
All the hemodynamic data are presented in Table 1.
Hemodynamic and Biochemical Data
Inhaled and intravenous milrinone reduced mean arterial
pressure. There was a more important decrease (P  .05) in
the intravenous milrinone group (55 6 mm Hg) compared
with that seen in the inhaled group (60  10 mm Hg) from
a preadministration mean arterial pressure of 75  10 mm
Hg. A decrease in systemic vascular resistance from 38  6
to 23  5 dynes · s1 cm5 · m2 in the intravenous
milrinone group was observed, whereas the systemic vas-
cular resistance did not change in the inhaled milrinone
group (P  .01).
Hemodynamic Data During and After Bypass
Blood pressure and cardiac index. In the CPB group
the mean arterial pressure and cardiac index were stable
throughout the study period, except for 30 minutes after
weaning of CPB, when there was an increase in systemic
blood pressure (P  .05) and cardiac index (P  .01).
Inhaled and intravenous milrinone blunted the peak ob-
served 30 minutes after the end of bypass.
Heart rate. There was a nonsignificant (P  .13)
increase in the heart rate during the bypass run in the
CPB group. The heart rate was increased (P  .05) in the
intravenous milrinone group compared with in the CPB
group and reached statistical significance only after 75
minutes of bypass (P  .05). The heart rate was signif-
icantly lower in the inhaled milrinone group compared
with in the CPB and intravenous milrinone groups at 15,
45, and 75 minutes during CPB and at 30 and 60 minutes
after CPB (P  0.05).
Oxygen exchanges. The alveolar-arterial oxygen gra-
dient was significantly greater in the intravenous milri-
none group 60 minutes after bypass (P  .05) compared
with in the CPB and inhaled milrinone groups. Oxygen
ic and Cardiovascular Surgery ● Volume 130, Number 1 89
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CSPexchanges were not different in the inhaled milrinone and
CPB groups.
There was no statistical difference in PAP, pulmonary
artery occlusion pressure (wedge), and central venous pres-
sure during the experiment within or between the groups
(data not shown).
Vascular Reactivity Studies
Contractions. The amplitude of contraction induced
by KCl (60 mmol/L) was similar in all groups (Table 2).
The concentration of PE necessary to reach 50% of the
contraction induced by 60 mmol/L KCl was greater in the
inhaled milrinone group compared with in the control
group (P  .05) and the intravenous milrinone group (P
 .01).
Relaxation. CPB induced an endothelial dysfunction, as
suggested by the reduced potency and efficacy of acetyl-
choline (P  .05; Figure 1, A). This dysfunction was pre-
vented by inhaled milrinone (P  .05) but not intravenous
milrinone.
Bradykinin-induced relaxations were also altered by
CPB (Fig 1, B ). Inhaled milrinone increased relaxation
to bradykinin compared with that seen in all other
groups (P  .05). In addition, no statistically significant
differences in relaxation to SNP were observed between
groups, with all rings achieving 100% relaxation (data
not shown).
cAMP measurements. The cAMP content was signifi-
cantly lower in the CPB group than in the control group (P
 .05). The cAMP content in the intravenous milrinone
group was similar to that seen in the control group. The
inhaled milrinone group had a higher content of cAMP than
the CPB group but less than the CPB and the intravenous
milrinone groups (P  .05, Figure 2).
Discussion
The aim of this study was to compare the effects of
preoperative inhaled and intravenous milrinone on the
endothelial dysfunction of pulmonary arteries induced by
CPB. The major findings of this study are that (1) CPB
induces a pulmonary endothelial dysfunction of the ace-
tylcholine (an agonist of M2 receptor coupled to Gi
proteins) and bradykinin (an agonist of B2 receptors
coupled to Gq protein) pathways that is reversed by
administration of inhaled but not intravenous milrinone
before CPB; (2) inhaled milrinone is associated with
better hemodynamic and oxygenation profiles than intra-
venous milrinone, with less hypotension, a lower heart
rate, and a lesser reduction in systemic vascular resis-
tances; and (3) intravenous milrinone causes an increase
in the alveolar-arterial oxygen gradient.
These observations suggest that the administration of
inhaled milrinone before CPB prevents pulmonary endothe-
90 The Journal of Thoracic and Cardiovascular Surgery ● July 2lial dysfunction with a superior pharmacodynamic profile
than the administration of intravenous milrinone.
Cardiac surgery with CPB can be associated with the
occurrence of PH. PH increases right ventricular work,
which can lead to right ventricular dysfunction, which
carries a poor prognosis and a perioperative mortality
ranging from 44% to 86%.6,9 Morita and colleagues10
have demonstrated in a porcine model that CPB causes a
significant increase in pulmonary vascular resistance and
decreases the right ventricular function by more than
50%. Pulmonary artery endothelial dysfunction caused
by a decrease in the production or increased degradation
of relaxing factors results in PH, leading to right ventric-
ular dysfunction and low cardiac output syndrome.11
Consequently, prevention of PH after CPB is of utmost
clinical importance, particularly in patients with pre-
existing PH.
Two modes of administration of the frequently used
drug milrinone were compared in a model with CPB. The
dose used was similar to human doses, approximately 0.5
g/kg for the loading dose. To date, only one study had
reported the use of inhaled milrinone after cardiac sur-
gery.7 Thus far, no experimental study had been per-
formed in a relevant animal model comparing 2 modes of
administration of milrinone in a reproducible swine
model of CPB associated with postoperative pulmonary
endothelial dysfunction.
In this study the doses of phenylephrine used to con-
tract the pulmonary arteries were higher in the inhaled
milrinone group than in the control and intravenous mil-
rinone groups. These higher doses might reflect a relative
pulmonary vasoplegia caused by an increased bioavail-
ability of cAMP (Figure 2). A lesser response of vascular
smooth muscle cells to contracting agents could have
beneficial implications in states of lower endothelial NO
production, as observed with the lower pulmonary vas-
cular resistance in the inhaled milrinone group. The re-
ductions in pulmonary resistance and right-sided after-
load observed in the inhaled milrinone group are the
likely causes of the observed increased stroke volume,
which is a favorable event in the postoperative setting.
The impairment of acetylcholine- and bradykinin-
induced endothelium-dependent relaxations in the CPB
group compared with in the control group was prevented by
inhaled milrinone but not by intravenous milrinone. Milri-
none increases cAMP levels in smooth muscle cells, leading
to vasorelaxation. The present experiments were performed
in the absence of PGI2 production because of the use of
indomethacin. Consequently, the increased relaxations are
most likely caused by increased NO production or an aug-
mented smooth muscle response to NO. Fortier and col-
leagues12 recently showed that the use of inhaled PGI2
before CPB increased endothelium-dependent relaxations to
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Pbradykinin through increasing cAMP levels. Niwano and
associates13 described a cAMP-responsive element in the
endothelial NO synthase promoter by using beraprost, a
PGI2 receptor agonist, to enhance cAMP levels, which
increased exhaled nitric oxide synthase expression and en-
hanced NO bioavailability. Hence by augmenting cAMP
levels, milrinone might promote endothelial NO production,
whereas selective administration in the pulmonary tree lim-
its the systemic side effects.
The speculative reasons why the 2 modes of adminis-
tration of milrinone achieved different effects on endo-
thelium-dependent relaxations are numerous. Because in-
travenous milrinone has an important distribution
volume, the precise amount of this drug reaching the
lungs is unknown. Furthermore, tachycardia and hypo-
tension could adversely affect the pulmonary endothelial
function. Inhaled milrinone was administered as a bolus
before initiation of CPB and followed by a continuous
nebulization throughout CPB. The dosages were extrap-
olated from human dosages and previous local experi-
ments. The amount of milrinone reaching the lungs by
means of nebulization was not quantified in the present
experiments. Administration of milrinone through nebu-
lization should not induce V/Q mismatch because only
vessels of ventilated regions of the lung are reached by
the molecule. On the other hand, intravenous milrinone
caused general vasodilatation, resulting in shunting and a
higher alveolar-arterial oxygen gradient. We believe that
the initial bolus of inhaled milrinone is responsible for
the majority of the effect compared with the continuous
nebulization because the 3 cm H2O positive end-expira-
tory pressure applied during CPB does not favor pene-
tration of the particles in the parenchyma. Furthermore,
only 10% of the initial dose of milrinone was nebulized
over the total CPB time, corresponding to approximately
15% of the pharmacologic dose of intravenous milrinone.
Haraldsson and colleagues7 reported a reduction in pul-
monary vascular resistance without side effects in patients
with PH receiving inhaled milrinone. No changes in mean
PAP were observed in this healthy swine model, as well as
no side effects. Beneficial effects in terms of oxygenation
and heart rate were observed. The wide variation between
the animals’ mean PAPs and the absence of pre-existing PH
could partially explain the lack of significant change in
mean PAP.
The smaller reduction in arterial pressure and in systemic
vascular resistance in the inhaled milrinone group compared
with intravenous administration is interesting because intra-
venous milrinone causes a significant systemic vasodilata-
tion. Inhaled milrinone is associated with a safer profile,
with lesser systemic actions.
The tachycardia associated with CPB was prevented by
inhaled milrinone, whereas intravenous milrinone increased
The Journal of Thoracthe heart rate compared with that seen in the CPB alone
group. The decrease in myocardial oxygen demand associ-
ated with a slower heart rate is an additional advantage of
inhaled milrinone.
Clinical Relevance
CPB is used every day in cardiac surgery. Despite a rela-
tively low prevalence of postoperative PH, various degrees
of pulmonary endothelial dysfunction occur in some subsets
or all of the patients with or without clinically apparent
manifestations. On the other hand, risk factors for postop-
erative PH are well known, and the patients could benefit
from prophylactic agents to lower their risk of development
of this important complication and its deleterious conse-
quences on right ventricular function. This article presents a
new mode of administration for milrinone, a drug used for
years in cardiac surgery. Inhaled milrinone is more effective
and associated with less hypotension than the traditional
intravenous route. In addition, inhaled milrinone is not
associated with the alterations in oxygen exchange seen
with intravenous administration and reverses the pulmonary
endothelial dysfunction through prevention of ischemia-
reperfusion injury during CPB.
Limitations
The pharmacokinetics of the drugs in the plasma and lung
parenchyma were not measured. The dose used in this study
was extrapolated from the literature and our clinical experi-
ence. Further studies to determine the best timing for an
inhaled milrinone bolus, namely before or after CPB, are
ongoing. Finally, a model with young and healthy 8-week-old
Landrace swine might not allow confirmation that inhaled
milrinone has similar beneficial effects in patients with coro-
nary artery disease and pre-existing pulmonary diseases. Car-
dioplegic arrest was not used in these experiments but is
unlikely to change the effects of CPB on pulmonary endothe-
lial function and gas exchange, although myocardial global
ischemia is known to increase inflammation.
Conclusion
This study comparing the effects of 2 modes of administration
of milrinone in swine undergoing CPB showed that inhaled
milrinone is safer and is associated with a lower heart rate
throughout the operation. It completely prevented the pulmo-
nary endothelial dysfunction and was associated with better
oxygen exchange than its intravenous administration in this
pulmonary ischemia-reperfusion model. This therapy could be
useful in patients at risk for postoperative PH undergoing
cardiac surgery and in other settings of ischemia-reperfusion
injuries, such as lung transplantation. Trials in patients under-
going cardiac surgery are ongoing to explore the effects of this
mode of administration in the clinical arena.
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